Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said ...